Zydus Lifesciences stock faces profit pressure after Q2

Published on 11/13/2026 at 02:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Zydus Lifesciences stock reported strong September-quarter revenue growth despite a sharp decline in net profit. Higher expenses weighed on earnings.

Profit pressure meets strong growth

Revenue increased sharply in the September quarter, led by pharmaceutical operations.
Higher expenses reduced net profit and highlighted pressure on profitability.
Management is targeting a US launch of saroglitazar, subject to regulatory approval.

Zydus Lifesciences, INE010B01027, Illustration mit AI erstellt.

Zydus Lifesciences reported a mixed second quarter for fiscal 2027 on Wednesday, November 4, 2026. Consolidated revenue from operations rose 29.2 percent year over year to 79.096 billion Indian rupees, while net profit fell 26.6 percent to 9.255 billion Indian rupees, according to Business Standard.

Revenue growth, earnings under pressure

Total expenses climbed to 68.066 billion Indian rupees from 45.09 billion Indian rupees a year earlier. The result left investors weighing strong top-line momentum against weaker profitability in the September quarter.

Pharmaceutical operations contributed 83 percent of sales. India formulations revenue increased 18 percent year over year, while North America formulations revenue rose 21 percent as volume expansion and the US specialty business supported growth.

Management said branded products accounted for 16 percent of US sales and pointed to the planned approval and launch of saroglitazar in the United States. The drug is Zydus Lifesciences' first internally discovered new chemical entity, making regulatory progress and commercialization important future milestones.

Pipeline adds a future catalyst

Zydus Therapeutics, a wholly owned subsidiary, also presented Phase 2b data for saroglitazar in adults with metabolic dysfunction-associated steatohepatitis at the 2026 meeting of the American Association for the Study of Liver Diseases. The 4 milligram dose achieved resolution of steatohepatitis without worsening of fibrosis in 39.1 percent of patients, compared with 13.7 percent for placebo, according to the BioSpace report. The study result supports the development program but does not by itself establish regulatory approval.

Business model and competitive position

Zydus Lifesciences develops and sells generic and branded medicines, specialty products, biosimilars, vaccines and active pharmaceutical ingredients, alongside consumer wellness products and medical devices. Its main markets include India, North America, Europe, Latin America and other emerging economies, and the group is headquartered in Ahmedabad, India. StockExact describes Zydus as the third-largest US generic-drug company by prescriptions; Sun Pharmaceutical Industries, Torrent Pharmaceuticals and Cipla are among the listed pharmaceutical peers closest to it in size.